$0.19 EPS Expected for Lantheus Holdings Inc (LNTH) This Quarter

Share on StockTwits

Equities analysts expect that Lantheus Holdings Inc (NASDAQ:LNTH) will report earnings per share (EPS) of $0.19 for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Lantheus’ earnings, with the lowest EPS estimate coming in at $0.15 and the highest estimate coming in at $0.22. Lantheus reported earnings per share of $0.24 during the same quarter last year, which would suggest a negative year-over-year growth rate of 20.8%. The company is scheduled to report its next quarterly earnings report after the market closes on Tuesday, October 30th.

According to Zacks, analysts expect that Lantheus will report full year earnings of $0.87 per share for the current fiscal year, with EPS estimates ranging from $0.81 to $0.93. For the next year, analysts expect that the business will post earnings of $1.04 per share, with EPS estimates ranging from $1.03 to $1.04. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Lantheus.

Lantheus (NASDAQ:LNTH) last released its earnings results on Wednesday, August 1st. The medical equipment provider reported $0.26 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.04. The firm had revenue of $85.60 million for the quarter, compared to the consensus estimate of $87.90 million. Lantheus had a net margin of 37.53% and a return on equity of 560.19%. The company’s revenue was down 3.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.35 EPS.

LNTH has been the subject of a number of research analyst reports. ValuEngine lowered shares of Lantheus from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 4th. BidaskClub downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Tuesday, September 25th. Zacks Investment Research upgraded Lantheus from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 4th. Credit Suisse Group lowered their target price on Lantheus from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Thursday, August 2nd. Finally, Wells Fargo & Co lowered their target price on Lantheus from $26.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, August 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $23.75.

Shares of NASDAQ:LNTH traded down $0.15 during midday trading on Tuesday, reaching $13.50. The company’s stock had a trading volume of 143,728 shares, compared to its average volume of 381,444. The company has a market capitalization of $517.05 million, a PE ratio of 13.50, a P/E/G ratio of 3.10 and a beta of 1.32. The company has a debt-to-equity ratio of 5.94, a current ratio of 3.86 and a quick ratio of 3.14. Lantheus has a 12-month low of $12.80 and a 12-month high of $24.45.

Several hedge funds have recently made changes to their positions in the business. Laurion Capital Management LP purchased a new stake in shares of Lantheus during the second quarter worth approximately $243,000. Itau Unibanco Holding S.A. bought a new position in shares of Lantheus during the second quarter valued at approximately $104,000. Boston Partners grew its holdings in shares of Lantheus by 198.1% during the second quarter. Boston Partners now owns 356,790 shares of the medical equipment provider’s stock valued at $5,191,000 after purchasing an additional 237,090 shares during the last quarter. Vaughan Nelson Investment Management L.P. bought a new position in shares of Lantheus during the second quarter valued at approximately $21,246,000. Finally, Factorial Partners LLC bought a new position in shares of Lantheus during the second quarter valued at approximately $886,000. Institutional investors own 92.52% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.

Featured Article: Marijuana Stocks

Get a free copy of the Zacks research report on Lantheus (LNTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply